The refracture rate in subjects without baseline vertebral fracture in the FREEDOM placebo group was 6.8 per 100 subject-years vs 4.9 per 100 subject-years in the combined denosumab group from the Extension (HR [95% CI]: 0.81 [0.50–1.30]; P = 0.373; Fig.